Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/358,351external-prioritypatent/US5654307A/en
Application filed by Warner Lambert CofiledCriticalWarner Lambert Co
Priority claimed from PCT/US1995/000941external-prioritypatent/WO1995019774A1/en
Publication of MX9602110ApublicationCriticalpatent/MX9602110A/en
Epidermal growth factor inhibitors of formula (1), where: at least one, and as many as three of A-E are nitrogen, with the remaining atom(s) carbon, or any two contiguous positions in A-E taken together can be a single heteroatom, N, O or S, in which case one of the two remaining atoms must be carbon, and the other can be either carbon or nitrogen; X = O, S, NH or NR7, such that R7 = lower alkyl (1-4 carbon atoms), OH, NH2, lower alkoxy (1-4 carbon atoms) or lower monoalkylamino (1-4 carbon atoms); n = 0, 1, 2.
MX9602110A1994-01-251995-01-23Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family.
MX9602110A
(en)
Tricyclic compounds and method of inhibiting the tyrasin kinases receptors of the epidermal growth factor, pharmaceutical composition, methods of preventing the blastocites implantation and mammals treatment
Bicyclic compounds, method of inhibiting the tyrosine kinases receptors as epidermal growth factor, pharmaceutical composition, methods of preventing blastocyte implantation and treatment of mammals